Abstract
The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation. Members of the Cancer Target Discovery and Development Network synthesize recent insights into the different classes and characteristics of cancer therapeutic vulnerabilities.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1142-1155 |
| Number of pages | 14 |
| Journal | Cell |
| Volume | 184 |
| Issue number | 5 |
| DOIs | |
| State | Published - Mar 4 2021 |
Funding
Data generated by the CTD 2 Network can be found in the Data Portal and Dashboard. More information about the centers can be found on the Network web site. CTD 2 Centers are funded in part by NCI grants U01 CA217846, U01 CA217858, U01 CA217862, U01 CA217875, U01 CA176058, U01 CA217883, U01 CA217851, U01 CA217882, U01 CA217842, U01 CA217848, U01 CA21788, and U01 CA217864. W.K. and P.T. receive research support from Pfizer Oncology.
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
